TG Therapeutics announced presentations of new data on BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers meeting. Data from the ongoing ENABLE Phase 4 study show significant patient-reported improvements and strong disease control, complementing prior Phase 3 ULTIMATE trial results. Presentations will highlight BRIUMVI's efficacy, tolerability, and one-hour infusion benefits, supporting its differentiated treatment profile. The event is scheduled for May 27-29, 2026, in Charlotte, N.C., with detailed data available on TG's website.
TG Therapeutics remains a "Strong Buy" as its drug BRIUMVI shows strong market momentum with 63% year-over-year sales growth in Q1. The company raised its 2026 BRIUMVI sales guidance to $885–$900 million, supported by successful Phase 3 trial results...
TG Therapeutics announced that its CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 3, 2026. The event will be webcast live on the company's website. TG Therapeutics is ...
TG Therapeutics announced positive Phase 3 ENHANCE trial results demonstrating that a single 600 mg infusion of BRIUMVI for relapsing multiple sclerosis (RMS) provides bioequivalent drug exposure compared to the current two-dose initiation regimen. T...
